|
Antibacterial Therapies Drug Development Pipeline Review, 2017 |
Mar 23 2017 |
418 |
Global |
$3,995.00 |
|
|
Atopic Dermatitis - 5EU Drug Forecast and Market Analysis to 2024 |
Nov 3 2015 |
152 |
Europe |
$6,995.00 |
|
|
Atopic Dermatitis - Current and Future Players |
Nov 3 2015 |
58 |
Global |
$2,995.00 |
|
|
Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024 |
Nov 3 2015 |
143 |
Japan |
$4,995.00 |
|
|
Atopic Dermatitis - US Drug Forecast and Market Analysis to 2024 |
Nov 3 2015 |
146 |
USA |
$4,995.00 |
|
|
Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence |
May 1 2018 |
215 |
Asia Pacific |
$4,995.00 |
|
|
Cardiovascular Disorders Drug Development Pipeline Review, 2017 |
Mar 16 2017 |
432 |
Global |
$3,995.00 |
|
|
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018 |
Apr 1 2018 |
376 |
Global |
$3,995.00 |
|
|
Cosmeceuticals: Global Trends in Market Entry Strategies, Regulatory Framework, Next-Generation Products and Technologies |
Feb 1 2018 |
106 |
Global |
$2,995.00 |
|
|
Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018 |
Jun 29 2018 |
344 |
Global |
$3,995.00 |
|
|
Dry Eye Syndrome - 5EU Drug Forecast and Market Analysis to 2024 |
Nov 5 2015 |
197 |
Europe |
$6,995.00 |
|
|
Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2024 |
Nov 5 2015 |
192 |
China |
$4,995.00 |
|
|
Dry Eye Syndrome - Current and Future Players |
Nov 5 2015 |
84 |
Global |
$2,995.00 |
|
|
Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2024 |
Nov 5 2015 |
194 |
India |
$4,995.00 |
|
|
Dry Eye Syndrome - Japan Drug Forecast and Market Analysis to 2024 |
Nov 5 2015 |
194 |
Japan |
$4,995.00 |
|
|
Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2024 |
Nov 5 2015 |
196 |
USA |
$4,995.00 |
|
|
Evolving Pharmaceutical Marketing Strategies: Digital as a Key Component of Multichannel Marketing |
Jan 24 2017 |
63 |
Global |
$2,995.00 |
|
|
Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need |
Aug 1 2017 |
79 |
Global |
$6,995.00 |
|
|
Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms |
May 1 2018 |
68 |
Global |
$6,995.00 |
|
|
Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease |
Apr 1 2018 |
77 |
Global |
$6,995.00 |
|
|
Frontier Pharma: Women’s Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline |
Feb 1 2018 |
86 |
Global |
$6,995.00 |
|
|
Fungal Foot Infections Drug Development Pipeline Review, 2018 |
Mar 22 2018 |
58 |
Global |
$3,995.00 |
|
|
Gene Therapies: A Growing Pipeline and Approval of CAR-T Cell Therapies Reflect Increasing Commercial Appeal, Despite Difficulties Faced by products such as Glybera and Strimvelis |
Jan 1 2018 |
79 |
Global |
$2,995.00 |
|
|
Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design |
Mar 1 2017 |
117 |
Global |
$2,995.00 |
|
|
Global Cardiovascular Disease Drugs Market to 2023 - Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape |
Dec 1 2017 |
228 |
Global |
$4,995.00 |
|
|
Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis |
Jul 1 2017 |
136 |
Global |
$4,995.00 |
|
|
Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs |
Mar 31 2018 |
181 |
Global |
$4,995.00 |
|
|
Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer’s Disease and SMA Show Clinical and Commercial Potential |
Feb 7 2018 |
199 |
Global |
$4,995.00 |
|
|
Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape |
Aug 1 2017 |
132 |
Global |
$4,995.00 |
|
|
Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market |
Mar 1 2017 |
197 |
Global |
$4,995.00 |
|
